1989 Fiscal Year Final Research Report Summary
An analysis of bladder carcinomas by flow-cytometry
Project/Area Number |
62570715
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Urology
|
Research Institution | Asahikawa Medical College |
Principal Investigator |
YACHIKU Sunao Department of Urology, Asahikawa Medical College, 医学部, 教授 (60028579)
|
Co-Investigator(Kenkyū-buntansha) |
HASHIMOTO Hiroshi Department of Urology, Asahikawa Medical College, 医学部, 講師 (90180835)
|
Project Period (FY) |
1987 – 1988
|
Keywords | Flow-Cytometry / DNA / Bladder Carcinoma |
Research Abstract |
An analysis of DNA ploidy of bladder transitional cell carcinomas by flow-cytometry was performed. The correlation of various tumor factors (e.g. tumor grade, tumor stage, etc.) and the DNA ploidy was analyzed. 1. Tumor grade and DNA ploidy : 72 samples were analyzed, and 31 samples(43%) were non-diploid. 2 of 6 samples(33%) of the grade 1 tumors 6 of 17(35%) of the grade 2, and 23 of 49(47%) of the grade 3 were non- diploid. 2. Tumor stage and DNA ploidy : The pathological stage on the specimen of total eystectomy and DNA ploidy were analyzed. The percentages of non-diploid pattern were 100%(1/1) in Ta, 60%(3/5) in T1a, 38%(3/8) in T1b, 63%(5/8) in T2, 40%(4/10) in T3a, 43%(3/7) in T3b, and 50%(I/2) in T4 carcinomas. 3. So called downstaging by preoperative irradiation and DNA ploidy : The downstaging was observed in 7 cases(35%) of diploid cases, and 4 cases(36%) of non-diploid cases. 4. The change of the pattern of DNA ploidy by irradiation : No significant change of the pattern of DNA ploidy was seen before and after irradiation. 5. Prognosis and DNA ploidy : in the cases of tumor-free-survival over 3 years the DNA pattern was non-diploid in 8 cases(67%), and in the cases of cancer-death it was non-diploid in 7 cases(64%). Above mentioned data revealed no significant correlation between DNA ploidy and the various conventional factors and prognoses of the bladder carcinomas.
|